Head-to-head · WeighScore
Midi Health vs Wisp
The verdict
Wisp takes it — 75/100 to 56.4/100.
Wisp grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Midi Health | Wisp |
|---|---|---|
| WeighScore | 56.4/100 | 75/100 |
| Grade | C | C |
| Scorecard rank | #414 | #59 |
| Semaglutide | Not disclosed | $225/mo (compounded oral) |
| Tirzepatide | Not disclosed | $99/mo (starting dose, brand-name) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #414 · C
Strengths
- Available in all 50 states
- Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
- Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
- Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)
Where it loses points
- Does not accept Medicare, Medicaid, or Medi-Cal
- GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
- Menopause-focused — not the right fit for men or younger women whose main goal is weight loss
Graded #59 · C
Strengths
- Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
- LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
- Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary
Where it loses points
- Sublingual compounded semaglutide hasn't been tested in humans, per Wisp's own page — only the injectables have FDA efficacy data
- Pharmacy partners not named
- States served not listed publicly
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.